ANCA vasculitis induction management during the COVID-19 pandemic
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
As the severe acute respiratory syndrome coronavirus 2 pandemic evolved and became a global health threat, the safety of immunosuppression in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) became of utmost important for clinicians and patients. Although timely initiation of immunosuppressive therapy is critical to quell the acute inflammation and prevent AAV-associated mortality and morbidity, concerns for increased susceptibility to Coronavirus Disease 2019 (COVID-19), delayed viral clearance, and decreased humoral response to infection led to speculation about modification in induction therapy practices may be deployed by physicians caring for patients with AAV. This international retrospective cohort study investigated the influence of the COVID-19 pandemic on AAV induction therapy and patient outcomes in different parts of the world by studying differences in treatment regimens in the United States, United Kingdom, and Europe.
Date Issued
2021-11
Date Acceptance
2021-08-10
Citation
Kidney International Reports, 2021, 6 (11), pp.2903-2907
ISSN
2468-0249
Publisher
Elsevier
Start Page
2903
End Page
2907
Journal / Book Title
Kidney International Reports
Volume
6
Issue
11
Copyright Statement
© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/34426797
PII: S2468-0249(21)01365-6
Subjects
ANCA vasculitis
COVID pandemic
induction therapy
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2021-08-19